Moreover, the inhibition of TFAM expression facilitates the release of mtDNA into cytoplasm, and activates signaling pathways to modulate oncogenesis and it is crucial to develop novel small-molecule compounds to target mitochondrial RNA polymerase (POLRMT) to block mitochondrial transcription, thereby selectively blocking OXPHOS and curbing tumor cell proliferation in chemoresistant metastatic CRCs. The gene discussed is TFAM; the disease is neoplasm.